{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:46:27Z","timestamp":1790405187245,"version":"4.1.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Weigao Research Fund of China Blood Transfusion Association","award":["CSBT-WG-2024-09"],"award-info":[{"award-number":["CSBT-WG-2024-09"]}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024ZYD0073"],"award-info":[{"award-number":["2024ZYD0073"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Although significant progress has been made in immune-targeted therapy for multiple myeloma (MM), it remains highly recurrent and incurable. Consequently, there is still an urgent need to develop more effective strategies against the recurrent and refractory tumor subsets. LILRB4, which is expressed on MM and Myeloid-Derived Suppressor Cells (MDSC) and plays an important role in promoting tumor progression and regulating the immuno-suppressive microenvironment. Therefore, it is an attractive target for MM treatment. We developed a bispecific natural killer cell engager (BiKE), LILRB4\/CD16A, to mediate NK cell-mediated lysis of MM cells. BiKE combined with CD16A strongly activated NK cells derived from human peripheral blood, and at the same time, BiKE bridged tumor cells to NK cells and promoted NK cytotoxicity, showing significant antitumor activity against LILRB4-high MM cells. NK cell cytotoxicity was further enhanced by the combined stimulation of innate immunity using cGAS-STING signaling agonists. In xenograft MM tumor models in immunodeficient mice, NK cells derived from human peripheral blood and expanded in vitro were combined with BiKE and cGAS-STING signaling agonists, demonstrating effective anti-tumor activity and inhibition of MM cell proliferation. Collectively, the combination of cGAS-STING agonists and LILRB4-targeting NK cell engagers offers a promising approach for treating relapsed\/refractory MM.<\/jats:p>","DOI":"10.1371\/journal.pone.0339375","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:42:46Z","timestamp":1766169766000},"page":"e0339375","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The combination of LILRB4-targeting NK cell engagers and cGAS\u2013STING agonists enhances the anti\u2013multiple myeloma immune activity of NK cells"],"prefix":"10.1371","volume":"20","author":[{"given":"Meng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-6171","authenticated-orcid":true,"given":"Xuemei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"6","key":"pone.0339375.ref001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"D Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"pone.0339375.ref002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New Biological Therapies for Multiple Myeloma","volume":"75","author":"AL Garfall","year":"2024","journal-title":"Annu Rev Med"},{"issue":"1","key":"pone.0339375.ref003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","volume":"11","author":"D Liu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"pone.0339375.ref004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"D Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"pone.0339375.ref005","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1182\/blood-2022-159289","article-title":"Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma","volume":"140","author":"Z Cao","year":"2022","journal-title":"Blood"},{"issue":"7","key":"pone.0339375.ref006","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"E Hatjiharissi","year":"2007","journal-title":"Blood"},{"issue":"11","key":"pone.0339375.ref007","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00262-009-0700-0","article-title":"Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing","volume":"58","author":"TE Kute","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"pone.0339375.ref008","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3892\/or.2014.3077","article-title":"Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS\/BRAF mutational status in colorectal cancer","volume":"31","author":"Y Seo","year":"2014","journal-title":"Oncol Rep"},{"issue":"2","key":"pone.0339375.ref009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/cancers13020312","article-title":"Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells","volume":"13","author":"KJ Dixon","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"27","key":"pone.0339375.ref010","article-title":"Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy","volume":"6","author":"KM Au","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"pone.0339375.ref011","article-title":"Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells","volume":"13","author":"Y Li","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"pone.0339375.ref012","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41375-021-01478-w","article-title":"A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma","volume":"36","author":"S Kakiuchi-Kiyota","year":"2022","journal-title":"Leukemia"},{"issue":"7728","key":"pone.0339375.ref013","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"M Deng","year":"2018","journal-title":"Nature"},{"issue":"11","key":"pone.0339375.ref014","first-page":"3650","article-title":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","volume":"109","author":"L Gong","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"pone.0339375.ref015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41419-024-06883-4","article-title":"LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway","volume":"15","author":"L Xie","year":"2024","journal-title":"Cell Death Dis"},{"issue":"15","key":"pone.0339375.ref016","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/bloodadvances.2022009477","article-title":"Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing","volume":"7","author":"Z Sun","year":"2023","journal-title":"Blood Adv"},{"key":"pone.0339375.ref017","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2024-202920","article-title":"Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma","volume":"144","author":"Y Wang","year":"2024","journal-title":"Blood"},{"issue":"11","key":"pone.0339375.ref018","first-page":"3650","article-title":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","volume":"109","author":"L Gong","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"pone.0339375.ref019","article-title":"Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches","volume":"19","author":"LT Khoo","year":"2018","journal-title":"EMBO Rep"},{"issue":"10","key":"pone.0339375.ref020","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/0008-5472.CAN-24-2531","article-title":"Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer","volume":"85","author":"F Pedretti","year":"2025","journal-title":"Cancer Res"},{"issue":"9","key":"pone.0339375.ref021","article-title":"Manganese boosts natural killer cell function via cGAS-STING mediated UTX expression","volume":"5","author":"Q Ming","year":"2024","journal-title":"MedComm (2020)"},{"issue":"2","key":"pone.0339375.ref022","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7150\/ijbs.65019","article-title":"Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer","volume":"18","author":"X Yan","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"9","key":"pone.0339375.ref023","doi-asserted-by":"crossref","first-page":"113108","DOI":"10.1016\/j.celrep.2023.113108","article-title":"STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells","volume":"42","author":"L Lu","year":"2023","journal-title":"Cell Rep"},{"key":"pone.0339375.ref024","doi-asserted-by":"crossref","first-page":"1039969","DOI":"10.3389\/fimmu.2022.1039969","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"SK Nikkhoi","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0339375.ref025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40425-019-0652-7","article-title":"IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells","volume":"7","author":"YH Choi","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"14","key":"pone.0339375.ref026","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"DA Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"pone.0339375.ref027","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"G Walsh","year":"2022","journal-title":"Nat Biotechnol"},{"key":"pone.0339375.ref028","doi-asserted-by":"crossref","first-page":"1215233","DOI":"10.3389\/fbioe.2023.1215233","article-title":"Sustained release of a highly specific GSK3\u03b2 inhibitor SB216763 in the PCL scaffold creates an osteogenic niche for osteogenesis, anti-adipogenesis, and potential angiogenesis","volume":"11","author":"W Gong","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"9","key":"pone.0339375.ref029","doi-asserted-by":"crossref","first-page":"109632","DOI":"10.1016\/j.celrep.2021.109632","article-title":"High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment","volume":"36","author":"VD Gonzalez","year":"2021","journal-title":"Cell Rep"},{"issue":"1","key":"pone.0339375.ref030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities-evolution in diagnosis and classification","volume":"482","author":"F Fend","year":"2023","journal-title":"Virchows Arch"},{"issue":"12","key":"pone.0339375.ref031","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.4049\/jimmunol.1401869","article-title":"STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells","volume":"193","author":"J Klarquist","year":"2014","journal-title":"J Immunol"},{"key":"pone.0339375.ref032","doi-asserted-by":"crossref","first-page":"110972","DOI":"10.1016\/j.biopha.2020.110972","article-title":"cGAS-STING signaling in cancer immunity and immunotherapy","volume":"133","author":"H Du","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"pone.0339375.ref033","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-Infiltrating Natural Killer Cells","volume":"11","author":"B C\u00f3zar","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0339375.ref034","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer","volume":"11","author":"M Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"pone.0339375.ref035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-030-87849-8_16","article-title":"Biology of NK Cells and NK Cells in Clinic.","volume-title":"Gene and Cellular Immunotherapy for Cancer","author":"GC Birch","year":"2022"},{"issue":"5562","key":"pone.0339375.ref036","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"L Ruggeri","year":"2002","journal-title":"Science"},{"issue":"4","key":"pone.0339375.ref037","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"C Fauriat","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"pone.0339375.ref038","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"V Jurisic","year":"2007","journal-title":"Med Oncol"},{"issue":"18","key":"pone.0339375.ref039","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"YM El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0339375.ref040","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.beha.2020.101141","article-title":"CAR T and CAR NK cells in multiple myeloma: Expanding the targets","volume":"33","author":"UA Shah","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"pone.0339375.ref041","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","article-title":"LILRB4, an immune checkpoint on myeloid cells","volume":"4","author":"T Yang","year":"2022","journal-title":"Blood Sci"},{"issue":"1","key":"pone.0339375.ref042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/15384101.2015.1121324","article-title":"Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors","volume":"15","author":"X Kang","year":"2016","journal-title":"Cell Cycle"},{"issue":"5701","key":"pone.0339375.ref043","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural killer cell signaling pathways","volume":"306","author":"E Vivier","year":"2004","journal-title":"Science"},{"key":"pone.0339375.ref044","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/B978-0-12-396962-0.00011-2","article-title":"Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier","volume":"503","author":"WM Pardridge","year":"2012","journal-title":"Methods Enzymol"},{"issue":"1","key":"pone.0339375.ref045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"J Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"17","key":"pone.0339375.ref046","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-17-2807","article-title":"Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine","volume":"24","author":"YS Tan","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0339375.ref047","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response","volume":"49","author":"A Marcus","year":"2018","journal-title":"Immunity"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:42:55Z","timestamp":1766169775000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339375"}},"subtitle":[],"editor":[{"given":"Xiaosheng","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339375","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}